“Josh Hardy’s story brought to public attention the often-devastating impact of adenovirus infection, and helped accelerate a discussion between the FDA and Chimerix regarding the need for additional clinical development to assess brincidofovirs potential in adenovirus infection,” Chimerix said in a statement. “This study is expected to begin with Josh Hardy as the first patient enrolled on Wednesday, March 12, 2014.” The special 20-person trial avoids potential ethical problems and other complications of giving the unproven treatment to selective patients. Read more here: newsobserver/2014/03/11/3693746/durham-drug-company-will-give.html#storylink=cpy #savejosh
Posted on: Wed, 12 Mar 2014 01:06:44 +0000
Trending Topics
Recently Viewed Topics
© 2015